Vector Pharma FZCO
Vector Pharma FZCO is a Dubai-based pharmaceutical distributor and commercialization partner specializing in rare disease, oncology, and specialty therapeutics across the MENA and Turkey region, serving international pharma innovators through regional market access and named-patient programs.
- Company typePrivate
- Founded2019
- HeadquartersDubai, United Arab Emirates
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Vector Pharma FZCO does
Vector Pharma FZCO is a Dubai-based pharmaceutical distribution and commercialization company founded in 2019, specializing in rare diseases, oncology, and highly specialized therapeutics. The company serves as a regional gateway for international pharmaceutical innovators seeking to access the Middle East, North Africa, and Turkey (MENAT) markets, where it provides regulatory navigation, market entry, and named-patient program services. It is a founding member of the World Orphan Drug Alliance (WODA), which extends its commercial reach to 158 countries, and holds TRACE International certification alongside GDP and GDPR compliance.
The company's core operations revolve around acting as an exclusive or semi-exclusive commercialization partner for niche pharma manufacturers. Its product portfolio includes oncology assets such as Oncopeptides' Pepaxti (melflufen) and Syndax therapies, as well as rare disease treatments including Theratechnologies' EGRIFTA SV (tesamorelin) and Amryt Pharma's specialty products. Vector Pharma deploys a field force of Key Account Managers and Medical Science Liaisons to engage healthcare professionals, while partnering with EVERSANA and Cencora to extend its distribution and commercialization services infrastructure.
The business model is B2B, generating revenue through distribution margins on high-cost specialty pharmaceuticals and service fees for named-patient programs, regulatory submissions, and market access support. Customers are primarily pharmaceutical innovators — including Oncopeptides, Theratechnologies, Amryt Pharma, Chiesi, Syndax, and Cencora — rather than end patients. The company operates from Al Barsha, Dubai, with a lean team of approximately 16 employees, positioning itself as a focused regional specialist rather than a generalist distributor.
Vector Pharma FZCO firmographics
Firmographics- Name
- Vector Pharma FZCO
- Legal name
- Vector Pharma FZCO
- Website
- https://vectorpharma.me
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vector Pharma FZCO is a Dubai-based pharmaceutical distributor and commercialization partner specializing in rare disease, oncology, and specialty therapeutics across the MENA and Turkey region, serving international pharma innovators through regional market access and named-patient programs.
- Ownership category
- akta.pro rank
Vector Pharma FZCO industry classification
Industry- Product category
- Specialty Pharmaceutical Distribution
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)
Keywords
Where Vector Pharma FZCO is headquartered
LocationHeadquarters
- HQ city
- Dubai
- HQ country
- United Arab Emirates
- HQ region
- Middle East
Offices2 records
Markets served
Vector Pharma FZCO business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Others
Revenue model
- Product Distribution: Vector Pharma distributes pharmaceutical products for rare diseases and oncology in the MENA and Turkey region. Revenue is generated through revenue sharing arrangements with partner companies, such as the agreement with Oncopeptides where revenue is split on all Pepaxti sales in the region, with Vector carrying all costs through their existing structure.
- Named Patient Program Services: Sales made on a named patient basis, where doctors request supply of products directly from the manufacturer. This is a key distribution channel for access to treatments not yet fully registered in all markets.
- Commercial Services Partnership: Strategic partnership with EVERSANA providing commercialization services including consulting, market access, medical communication, pharmacovigilance, and distribution services to pharmaceutical companies expanding into Middle East and North African markets.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Vector Pharma FZCO product offering
Product offeringCore offering
Vector Pharma FZCO is a full-service pharmaceutical distribution and commercialization partner that distributes rare disease, oncology, and highly specialized therapeutics across the Middle East, North Africa, and Turkey (MENAT) region. The company operates as a founding member of the World Orphan Drug Alliance (WODA), providing integrated services spanning medical affairs, marketing and sales, market access, regulatory affairs, pharmacovigilance, logistics, and independent compliance for biotech and pharmaceutical manufacturers.
Product overview
Vector Pharma FZCO is a full-service pharmaceutical distribution company specializing in rare diseases, oncology, and highly specialized therapeutics across the MENA and Turkey region. The company operates as a unified platform combining distribution of branded pharmaceutical products (Pepaxti, EGRIFTA SV) with a comprehensive suite of integrated service modules including Medical Affairs, Marketing & Sales, Market Access, Pharmacovigilance/QA Support, Regulatory Affairs, Logistics and Tendering, and Independent Compliance. Vector Pharma serves as a founding member of the World Orphan Drug Alliance (WODA), enabling access to treatments across 158 countries through alliance partnerships. The company's go-to-market approach includes named patient programs for unlicensed medicines alongside full commercialization services.
Differentiator
Problem solved
Functional benefit
Products and services
- Pepaxti (melphalan flufenamide) Distribution Distribution of Pepaxti (melphalan flufenamide) for treatment of adults with multiple myeloma who have received at least three prior lines of therapy, used in combination with dexamethasone. Made available to patients across MENA on a named patient basis through partnership with Oncopeptides.
- EGRIFTA SV Distribution Distribution of EGRIFTA SV for adults living with HIV who have lipodystrophy and excess abdominal fat, distributed under WODA's Named Patient Program across 41 countries including MENAT markets.
- Medical Affairs Services Standalone service module providing scientific communication, clinical support, KOL engagement, education and training, market access support, patient advocacy, and real-world evidence collection for orphan and specialty medicines in MENAT.
- Marketing & Sales Services Standalone service module providing market understanding, targeted messaging, healthcare provider engagement, KOL collaboration, patient-centric approaches, and multi-channel marketing for rare disease and specialty pharmaceutical products in MENAT.
- Market Access Services Standalone service module providing reimbursement strategy development, Health Technology Assessments, pricing strategy, stakeholder engagement, real-world evidence generation, patient access programs, and policy advocacy for orphan medicines in MENAT.
- Regulatory Affairs Services Standalone service module providing documentation submission for product registration, regulatory compliance, labeling and packaging compliance, regulatory change monitoring, communication with regulatory authorities, clinical trial oversight, and post-market surveillance across MENAT markets.
- Pharmacovigilance/QA Support Services Standalone service module providing adverse event monitoring, safety profile evaluation, regulatory reporting, safety communication, database management, quality management systems, GDP compliance, audits and inspections, and deviation management.
- Logistics and Tendering Services Standalone service module providing supply chain management, inventory management, distribution planning, warehouse operations, transport coordination, tracking and reporting, tender management, market analysis, proposal development, and contract negotiation.
- Independent Compliance Services Standalone service module providing regulatory adherence, quality assurance, training and education, monitoring and auditing, risk management, reporting and documentation, ethical standards, incident management, and adaptation to regulatory changes.
Companies that use Vector Pharma FZCO
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles1 record
Vector Pharma FZCO technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Vector Pharma FZCO partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and minor.
- Oncopeptides ABcoreExclusive collaboration to commercialize Pepaxti (melphalan flufenamide) for the treatment of multiple myeloma in MENA countries including Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Revenue is split on all Pepaxti sales, with Vector carrying all costs through their existing regional structure.
- Theratechnologies Inc.majorLong-term multi-territorial distribution agreement for EGRIFTA SV in 41 countries through WODA. Under the agreement, adults living with HIV who have lipodystrophy and excess abdominal fat can access EGRIFTA SV in markets where it was previously not available. Vector Pharma covers MENAT markets as part of this agreement.
- EVERSANAcoreStrategic partnership to expand commercial services across Middle East and North African markets. EVERSANA and Vector Pharma now offer ready-to-deploy commercial services including consulting, market access, medical communication, pharmacovigilance, and distribution. This partnership aligns with EVERSANA's continued global growth in the European Union and United Kingdom.
- World Orphan Drug Alliance (WODA)coreVector Pharma is a founding member of the World Orphan Drug Alliance (WODA), a global alliance of commercial distributors providing access to treatments for rare diseases and specialty medicines in complex and underserved markets. WODA covers 158 countries across 6 continents through member organizations including Vector Pharma (MENAT), Medis (CEE), Orpharm (Russia/CIS), Orphan DC (LATAM), and others.
- Amryt PharmaminorPharmaceutical partner with therapies in rare diseases, hematology, and other highly specialized therapeutics. Partnership established in 2021.
- ChiesiminorPharmaceutical partner with rare disease and specialty therapeutics portfolio. Partnership established in 2024.
- Syndax PharmaceuticalsminorBiotechnology partner with oncology portfolio. Partnership established in 2025.
- Eversana (commercial services)coreNext-generation commercial services partner to the global life sciences industry. Strategic partnership announced in 2022 to expand services across MENAT markets, providing consulting, market access, medical communication, pharmacovigilance, and distribution services.
- CencoraminorPharmaceutical sourcing and distribution partner. Partnership established in 2025.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
Vector Pharma FZCO competitors and assessment
Company assessmentOthers
- Oncopeptides AB: Swedish biotech developing Pepaxti (melphalan flufenamide) for multiple myeloma. A Vector Pharma distribution partner in 12 MENA markets; representative of the innovative rare-disease/oncology biotechs whose MENA commercialization needs Vector is built to serve.
- Theratechnologies: Canadian specialty biopharma focused on rare-disease therapeutics including EGRIFTA SV (HIV lipodystrophy). A Vector Pharma distribution partner via WODA, and representative of the biotech client base that Vector serves — comparable as a counterparty profile if not as a direct competitor.
Direct peers
- OrphanDC: Latin American specialty orphan-drug distributor and WODA founding member. Operates the same regional rare-disease distribution-plus-services model as Vector Pharma and is directly comparable as a peer WODA regional node.
- Medis: Central and Eastern European specialty pharma distributor and fellow WODA founding member covering orphan and rare-disease medicines. Operates the same named-patient-program-to-full-commercialization model as Vector Pharma in its respective region, making it the closest structural twin.
- Inceptua Group: Specialty pharmaceutical company providing access to medicines not commercially available through managed access programs and comparator sourcing. Comparable to Vector Pharma in serving named-patient / managed-access demand for unlicensed rare-disease therapeutics.
- Clinigen Group: Global specialty pharmaceuticals and services company focused on access to unlicensed/unapproved medicines via managed access (named patient) programs and rare-disease commercialization. Highly comparable business model to Vector Pharma's named-patient-plus-distribution offering, though at much larger scale.
- Orpharm: Russia and CIS-focused orphan-drug distributor and WODA founding member. Mirrors Vector Pharma's regional distribution-plus-commercialization model for rare-disease therapeutics, with comparable named-patient and full commercialization capabilities.
Broad incumbents
- EVERSANA: Large US-headquartered commercial services platform for life sciences companies covering market access, medical communications, pharmacovigilance and distribution. Vector Pharma's strategic partner but also an overlapping commercial-services provider that competes for similar biotech mandates globally.
- Cencora (formerly AmerisourceBergen): One of the world's largest pharmaceutical wholesale distributors. Listed as a Vector Pharma partner for distribution services, Cencora operates at a fundamentally different scale but competes for the same specialty/orphan distribution mandates from global pharma manufacturers.
- McKesson: Global pharmaceutical distribution and healthcare services giant. Operates specialty distribution arms that compete with regional rare-disease distributors like Vector Pharma for biotech and pharma manufacturer distribution contracts.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Vector Pharma FZCO social profiles
Digital presenceVector Pharma FZCO compliance and trust
Trust signalCompliance3 records
Vector Pharma FZCO financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vector Pharma FZCO leadership team
Management profileNumber of profiles
Profiles3 records
Vector Pharma FZCO funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vector Pharma FZCO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vector Pharma FZCO
What does Vector Pharma FZCO do?
Vector Pharma FZCO is a full-service pharmaceutical distribution and commercialization partner that distributes rare disease, oncology, and highly specialized therapeutics across the Middle East, North Africa, and Turkey (MENAT) region. The company operates as a founding member of the World Orphan Drug Alliance (WODA), providing integrated services spanning medical affairs, marketing and sales, market access, regulatory affairs, pharmacovigilance, logistics, and independent compliance for biotech and pharmaceutical manufacturers.
Is Vector Pharma FZCO a public or private company?
Vector Pharma FZCO is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Vector Pharma FZCO founded?
Vector Pharma FZCO was founded in 2019. It employs 11 to 50 people.
Where is Vector Pharma FZCO based?
Vector Pharma FZCO is headquartered in Dubai, United Arab Emirates, in the Middle East region.
How does Vector Pharma FZCO make money?
Three revenue lines are on record. Product Distribution is the primary driver. The others are named Patient Program Services and commercial Services Partnership.
Who are Vector Pharma FZCO's main competitors?
Others on record are Oncopeptides AB and Theratechnologies. Direct peers are OrphanDC, Medis, Inceptua Group, Clinigen Group and Orpharm. Broad incumbents are EVERSANA, Cencora (formerly AmerisourceBergen) and McKesson.
Does Vector Pharma FZCO have an API?
No public API is recorded for Vector Pharma FZCO.
What industry is Vector Pharma FZCO in?
Vector Pharma FZCO's product category is Specialty Pharmaceutical Distribution. Its primary akta.pro industry code is CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 424210 and its SIC code is 5122.